Unstable Angina Pectoris During Ptca — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for unstable angina pectoris during ptca. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
8
Active US patents
69/100
Avg vulnerability
—
Annual revenue covered

Originators in Unstable Angina Pectoris During Ptca

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating unstable angina pectoris during ptca. Each bar = one year. Y-axis scaled to peak year (4 patents).

2
28
2
29
4
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Angiomax
BIVALIRUDIN
 Novartis 8 69 — 2028-07-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7582727 Angiomax other 75 2029-01-27
7598343 Angiomax other 75 2029-01-27
11903993 Angiomax method of use 75 2039-05-20
12472224 Angiomax method of use 75 2039-05-20
11918622 Angiomax method of use 75 2039-05-20
7582727 Angiomax formulation 60 2028-07-27
7598343 Angiomax formulation 60 2028-07-27
11992514 Angiomax formulation 55 2039-05-20

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11992514 Angiomax formulation 55 2039-05-20
7598343 Angiomax formulation 60 2028-07-27
7582727 Angiomax formulation 60 2028-07-27
12472224 Angiomax method of use 75 2039-05-20
11918622 Angiomax method of use 75 2039-05-20
11903993 Angiomax method of use 75 2039-05-20
7582727 Angiomax other 75 2029-01-27
7598343 Angiomax other 75 2029-01-27

Related